Jianersheng Pharmaceutical Technology

Guangdong Jianersheng Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of innovative therapies for heavy metal poisoning and detoxification. Founded by Dr. Tang Xiaojiang in collaboration with Da An Gene, the company utilizes a proprietary "intracellular toxin removal" platform that leverages glucose transporters (SGLT and GLUT) to deliver therapeutic agents into cells. Its lead candidate, GMDTC (Jindi Tixi), is a first-in-class small molecule designed to treat cadmium and lead poisoning and to mitigate the toxic side effects of platinum-based chemotherapy. Jianersheng also develops rapid diagnostic tools for heavy metal detection and is expanding its pipeline to address chronic kidney disease and other conditions associated with heavy metal exposure.